Member Exclusive
US-China Life Sciences Deals in an Era of Accelerating Innovation
8:30 AM – 9:30 AM Eastern Time
8:30 PM – 9:30 PM China Standard Time
Facing an estimated $370 billion revenue gap by 2032 driven by patent cliffs, life sciences companies continue their reliance on external innovation to sustain pipeline strength and growth. Over the past few years, China-based biopharma firms have seen an explosion in innovation-based R&D.
